Amyris - AMRS Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMRS, but not buy additional shares or sell existing shares.
View AMRS analyst ratings or view top-rated stocks.

4 analysts have issued 1 year price objectives for Amyris' stock. Their AMRS share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's share price to reach $4.67 in the next year. This suggests a possible upside of 195.4% from the stock's current price.
View analysts price targets for AMRS or view top-rated stocks among Wall Street analysts.

Amyris' stock was trading at $1.53 on January 1st, 2023. Since then, AMRS shares have increased by 3.3% and is now trading at $1.58.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our AMRS earnings forecast.

Amyris, Inc. (NASDAQ:AMRS) released its earnings results on Tuesday, November, 8th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.25. The biotechnology company earned $71.13 million during the quarter, compared to analyst estimates of $111.98 million.

Amyris shares reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Amyris updated its fourth quarter 2022 earnings guidance on Thursday, December, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $100.00M-, compared to the consensus revenue estimate of $138.39 million.

84 employees have rated Amyris Chief Executive Officer John Melo on Glassdoor.com. John Melo has an approval rating of 54% among the company's employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Amyris to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia Oyj (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Amyris' stock is owned by a number of retail and institutional investors. Top institutional investors include Pinnacle Associates Ltd. (1.26%), Wealth Alliance Advisory Group LLC (0.01%) and National Bank of Canada FI (0.00%). Insiders that own company stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr and Nicole Kelsey.
View institutional ownership trends.

Shares of AMRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRS stock can currently be purchased for approximately $1.58.

Amyris (NASDAQ:AMRS) has a market capitalization of $521.65 million and generates $341.82 million in revenue each year. The biotechnology company earns $-270,970,000.00 in net income (profit) each year or ($1.74) on an earnings per share basis.

The company employs 980 workers across the globe.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The official website for the company is amyris.com. The biotechnology company can be reached via phone at (510) 450-0761, via email at investor@amyris.com, or via fax at 510-225-2645.